Find disease awareness content and relevant supporting materials

Migraine is prevalent everywhere, and disabling. It is also neglected: consequently, it is under-diagnosed and undertreated. We analysed data from the Eurolight study on consultations and utilization of migraine-specific...

If it were needed, more evidence of the disconcerting under-treatment of headache disorders has come from the Eurolight study [1]. The topic is not new. Twenty years ago, the International and American Headache Societies jointly voiced ...

Objective: To study the weighted average global prevalence of migraine at the community level.

Vertex Pharmaceuticals Incorporated announced publication in the New England Journal of Medicine (NEJM) of results from preclinical studies and a Phase II study evaluating the efficacy and safety of inaxaplin (VX 147) on top of standard-of-care in people with focal segmental glomerulosclerosis (FSGS) and two APOL1 variants , a severe, rapidly progressive form of chronic kidney disease also known as APOL1-mediated kidney disease (AMKD). AMKD is caused by variants of the APOL1 gene and affects approximately 100,000 people in the U.S. and Europe. Inaxaplin is an APOL1 inhibitor aimed at treating the underlying cause of AMKD.

We evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with...

Background: The aim of the present study was to systematically review and analyze the available evidence on the role of surgery in improving outcomes in patients with migraine headaches.

Purpose of review: Migraine is a primary headache disorder and one of the most common and disabling neurological diseases worldwide.

Objective: To describe the development of the Impact of Migraine on Partners and Adolescent Children (IMPAC) scale.

Calcitonin gene-related peptide plays an important role in migraine pathophysiology. Erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.

Objective: To evaluate unmet needs from the perspective of HS patients.